Thomas Jefferson University

Jefferson Digital Commons
Phase 1

Class of 2022

1-2020

The Financial and Psychosocial Impact of Medicinal Cannabis
Andrew Lee
Thomas Jefferson University

Chris Ahmed
Thomas Jefferson University

Amanda Campbell
Thomas Jefferson University

Gregory Garber, MSW, LCSW
Thomas Jefferson University

Neil D. Palmisiano, MD
Thomas Jefferson University
Follow this and additional works at: https://jdc.jefferson.edu/si_hs_2022_phase1
See next page for additional authors
Part of the Oncology Commons

Let us know how access to this document benefits you
Recommended Citation
Lee, Andrew; Ahmed, Chris; Campbell, Amanda; Garber, MSW, LCSW, Gregory; Palmisiano, MD,
Neil D.; and Worster, MD, Brooke, "The Financial and Psychosocial Impact of Medicinal
Cannabis" (2020). Phase 1. Paper 6.
https://jdc.jefferson.edu/si_hs_2022_phase1/6
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Phase 1 by an authorized administrator of the Jefferson Digital Commons. For more
information, please contact: JeffersonDigitalCommons@jefferson.edu.

Authors
Andrew Lee; Chris Ahmed; Amanda Campbell; Gregory Garber, MSW, LCSW; Neil D. Palmisiano, MD; and
Brooke Worster, MD

This abstract is available at Jefferson Digital Commons: https://jdc.jefferson.edu/si_hs_2022_phase1/6

SKMC Class of 2022
Word count: 248

The Financial and Psychosocial Impact of Medicinal Cannabis
Andrew Lee, Chris Ahmed**, Amanda Campbell, Greg Garber, MSW, LCSW, Neil Palmisiano,
MD, Brooke Worster, MD*

Introduction: The use of medicinal cannabis for symptom management in cancer patients is a
growing area of clinical interest. Past studies have demonstrated cannabis’s potential as an
antiemetic and analgesic, but there is still much research to be done on its clinical efficacy. Our
study hypothesizes that cancer patients using medicinal cannabis experience subjective
improvements in pain, chemotherapy-induced nausea and vomiting (CINV), and quality of life
(QOL) that justify related out-of-pocket costs.
Methods: Cancer patients are surveyed by phone three to six months after certification for
access to medicinal cannabis. The survey assesses patient-reported changes in pain, CINV, QOL,
and financial burden. Patient responses are documented as changes in satisfaction compared to
baseline satisfaction using a Likert scale (1-5; 1 = greatly decreased satisfaction, 5 = greatly
increased satisfaction). Aggregate scores over 3.5 indicate meaningful symptomatic
improvement.
Results: The initial 35 surveys (desired n = 120) show moderately increased satisfaction with
CINV and pain relief (3.63 and 3.53, respectively), with mildly increased satisfaction with QOL
(3.46). Patients report meaningful improvements in nausea, mood, ability to function in daily

life, and pain interference with sleep and general activity. Patients generally do not report
decreased financial satisfaction (3.03).
Conclusion: Preliminary data suggests that medicinal cannabis may provide analgesic,
antiemetic, and anxiolytic benefits for cancer patients. If future surveys yield similar results, we
anticipate that our study could support the use of medicinal cannabis as a cost-effective
adjunctive therapy for cancer patients suffering treatment or cancer related side effects.

